AU2018318425A1 - Methods of treatment of osteoarthritis with transdermal cannabidiol gel - Google Patents

Methods of treatment of osteoarthritis with transdermal cannabidiol gel Download PDF

Info

Publication number
AU2018318425A1
AU2018318425A1 AU2018318425A AU2018318425A AU2018318425A1 AU 2018318425 A1 AU2018318425 A1 AU 2018318425A1 AU 2018318425 A AU2018318425 A AU 2018318425A AU 2018318425 A AU2018318425 A AU 2018318425A AU 2018318425 A1 AU2018318425 A1 AU 2018318425A1
Authority
AU
Australia
Prior art keywords
cbd
pain
cannabidiol
patients
osteoarthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018318425A
Other languages
English (en)
Inventor
Daniel Clauw
James GRIESSER
Donna Gutterman
John MESSENHEIMER
Ted Smith
Nancy TICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zynerba Pharmaceuticals Inc
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of AU2018318425A1 publication Critical patent/AU2018318425A1/en
Priority to AU2024205778A priority Critical patent/AU2024205778A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2018318425A 2017-08-14 2018-08-13 Methods of treatment of osteoarthritis with transdermal cannabidiol gel Abandoned AU2018318425A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205778A AU2024205778A1 (en) 2017-08-14 2024-08-15 Methods of treatment of osteoarthritis with transdermal cannabidiol gel

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545468P 2017-08-14 2017-08-14
US62/545,468 2017-08-14
US201862661733P 2018-04-24 2018-04-24
US62/661,733 2018-04-24
PCT/IB2018/056090 WO2019034985A1 (en) 2017-08-14 2018-08-13 METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205778A Division AU2024205778A1 (en) 2017-08-14 2024-08-15 Methods of treatment of osteoarthritis with transdermal cannabidiol gel

Publications (1)

Publication Number Publication Date
AU2018318425A1 true AU2018318425A1 (en) 2020-02-27

Family

ID=65362584

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018318425A Abandoned AU2018318425A1 (en) 2017-08-14 2018-08-13 Methods of treatment of osteoarthritis with transdermal cannabidiol gel
AU2024205778A Pending AU2024205778A1 (en) 2017-08-14 2024-08-15 Methods of treatment of osteoarthritis with transdermal cannabidiol gel

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205778A Pending AU2024205778A1 (en) 2017-08-14 2024-08-15 Methods of treatment of osteoarthritis with transdermal cannabidiol gel

Country Status (11)

Country Link
US (4) US20200170963A1 (cg-RX-API-DMAC7.html)
EP (1) EP3668500A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020530857A (cg-RX-API-DMAC7.html)
KR (1) KR20200054171A (cg-RX-API-DMAC7.html)
AU (2) AU2018318425A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020003025A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072849A1 (cg-RX-API-DMAC7.html)
IL (2) IL301622A (cg-RX-API-DMAC7.html)
JO (1) JOP20200031A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020001768A (cg-RX-API-DMAC7.html)
WO (1) WO2019034985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
IL325123A (en) 2018-12-14 2026-02-01 Harmony Biosciences Man Inc Treating 22q11.2 Deficiency Syndrome with Cannabidiol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4725549A3 (en) * 2019-10-13 2026-06-10 FibroBiologics, Inc. Cannabidiol adjuvant therapy for treatment of disc degenerative disease
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
TWI902836B (zh) * 2020-06-29 2025-11-01 美商和諧生物科學管理股份有限公司 以大麻二酚(cannabidiol)治療X染色體脆折症候群
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
JP2025535174A (ja) * 2022-10-17 2025-10-22 インベンテージ ラボ インコーポレイテッド 炎症性疾患の治療または予防のための徐放型注射用組成物およびその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
DK2376121T4 (da) * 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
EP2864477A4 (en) * 2012-06-26 2016-02-17 Amberdale Entpr Pty Ltd ISOLATION OF STEM CELLS FROM ADIPOSE TISSUE BY ULTRASONIC CAVITATION, AND METHODS OF USE
WO2016011451A1 (en) * 2014-07-18 2016-01-21 Medipath, Inc. Compositions and methods for physiological delivery using cannabidiol
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法

Also Published As

Publication number Publication date
US20200170963A1 (en) 2020-06-04
KR20200054171A (ko) 2020-05-19
JP2023109969A (ja) 2023-08-08
BR112020003025A2 (pt) 2020-08-04
CA3072849A1 (en) 2019-02-21
MX2020001768A (es) 2020-12-03
EP3668500A4 (en) 2021-04-28
WO2019034985A1 (en) 2019-02-21
JP7590803B2 (ja) 2024-11-27
JP2020530857A (ja) 2020-10-29
EP3668500A1 (en) 2020-06-24
JP2025024068A (ja) 2025-02-19
US20250268843A1 (en) 2025-08-28
US20240148669A1 (en) 2024-05-09
IL301622A (en) 2023-05-01
IL272593A (en) 2020-03-31
US20240189255A1 (en) 2024-06-13
JOP20200031A1 (ar) 2020-02-12
AU2024205778A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US20240148669A1 (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel
US20250302734A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
JP7210564B2 (ja) カンナビジオールによる脆弱x症候群の処置
WO2022003541A1 (en) Treatment of fragile x syndrome with cannabidiol
AU2009304002B2 (en) A medicinal product and treatment
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
KR20240093852A (ko) 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료
Joseph et al. Efinaconazole 10% solution in the treatment of onychomycosis of the toenails
RU2830586C1 (ru) Композиции на основе диклофенака для местного применения и связанные с ними способы
EP4098254A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
Ongzalima et al. The Foot and Ankle Online Journal
AU2015419323A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
HK1263116A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MESSENHEIMER, JOHN; TICH, NANCY; GUTTERMAN, DONNA; CLAUW, DANIEL; GRIESSER, JAMES AND SMITH, TED

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted